<DOC>
	<DOCNO>NCT01658579</DOCNO>
	<brief_summary>Primary Objective : - To compare glucose control treatment new formulation insulin glargine Lantus adult participant type 1 diabetes mellitus Secondary Objectives : - To compare new formulation insulin glargine Lantus give morning even - To compare incidence frequency hypoglycemic episodes - To assess safety tolerability new formulation insulin glargine</brief_summary>
	<brief_title>Comparison New Formulation Insulin Glargine With Lantus Patients With Type 1 Diabetes Mellitus Basal Plus Mealtime Insulin</brief_title>
	<detailed_description>- Up 4-week screening period ; - 16-week open-label comparative efficacy safety treatment period ; - 4-week post-treatment safety follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Participants Type 1 diabetes mellitus Exclusion criterion : HbA1c great ( &gt; ) 9 % ( screen ) Participants receive &gt; 0.5 U/kg body weight basal insulin last 30 day prior screen visit Participants stable insulin dose ( +/ 20 % total basal insulin dose ) last 30 day prior screen visit Less 1 year basal plus mealtime insulin Participants use premix insulin , human regular insulin mealtime insulin and/or antidiabetic drug basal insulin mealtime analogue insulin last 3 month screen visit Use insulin pump last 6 month screen visit ; Any contraindication use insulin glargine define national product label Not willing inject insulin glargine assign randomization process daily morning even Hospitalization diabetic ketoacidosis history severe hypoglycemia ( require 3rd party assistance ) last 6 month prior randomization Initiation glucoselowering agent last 3 month screen visit Weight change great equal ( &gt; = ) 5 kg last 3 month prior screen visit Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require laser , surgical treatment injectable drug study period The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>